JP2021531311A5 - - Google Patents

Info

Publication number
JP2021531311A5
JP2021531311A5 JP2021504235A JP2021504235A JP2021531311A5 JP 2021531311 A5 JP2021531311 A5 JP 2021531311A5 JP 2021504235 A JP2021504235 A JP 2021504235A JP 2021504235 A JP2021504235 A JP 2021504235A JP 2021531311 A5 JP2021531311 A5 JP 2021531311A5
Authority
JP
Japan
Prior art keywords
membered
alkyl
cycloalkyl
aryl
substituted
Prior art date
Application number
JP2021504235A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020023551A5 (https=
JP7386842B2 (ja
JP2021531311A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/043112 external-priority patent/WO2020023551A1/en
Publication of JP2021531311A publication Critical patent/JP2021531311A/ja
Publication of JPWO2020023551A5 publication Critical patent/JPWO2020023551A5/ja
Publication of JP2021531311A5 publication Critical patent/JP2021531311A5/ja
Application granted granted Critical
Publication of JP7386842B2 publication Critical patent/JP7386842B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021504235A 2018-07-24 2019-07-23 ナフチリジン化合物およびその使用 Active JP7386842B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018096781 2018-07-24
CNPCT/CN2018/096781 2018-07-24
PCT/US2019/043112 WO2020023551A1 (en) 2018-07-24 2019-07-23 Naphthyridine compounds and uses thereof

Publications (4)

Publication Number Publication Date
JP2021531311A JP2021531311A (ja) 2021-11-18
JPWO2020023551A5 JPWO2020023551A5 (https=) 2022-07-22
JP2021531311A5 true JP2021531311A5 (https=) 2022-07-22
JP7386842B2 JP7386842B2 (ja) 2023-11-27

Family

ID=67551416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021504235A Active JP7386842B2 (ja) 2018-07-24 2019-07-23 ナフチリジン化合物およびその使用

Country Status (6)

Country Link
US (1) US12297210B2 (https=)
EP (1) EP3826721B1 (https=)
JP (1) JP7386842B2 (https=)
CN (1) CN112533677A (https=)
TW (1) TW202012405A (https=)
WO (1) WO2020023551A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113454070A (zh) * 2018-09-30 2021-09-28 豪夫迈·罗氏有限公司 噌啉化合物及用于hpk1依赖性疾患诸如癌症的治疗
TWI721623B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
TW202136261A (zh) 2018-10-31 2021-10-01 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
EP4090663A1 (en) 2020-01-15 2022-11-23 Blueprint Medicines Corporation Map4k1 inhibitors
WO2022063140A1 (en) * 2020-09-23 2022-03-31 Shenzhen Ionova Life Science Co., Ltd. Pyrimidine and pyridine derivatives as hpk1 modulator and methods using same
CN114907375B (zh) * 2021-02-07 2026-03-31 苏州信诺维医药科技股份有限公司 杂环化合物、其制备方法、药物组合物及应用
CN114907374B (zh) * 2021-02-07 2026-03-10 苏州信诺维医药科技股份有限公司 杂环化合物、其制备方法、药物组合物及应用
KR20240083168A (ko) * 2021-07-14 2024-06-11 블루프린트 메디신즈 코포레이션 Map4k1 저해제로서의 헤테로사이클 화합물
US20240336630A1 (en) * 2021-07-15 2024-10-10 Blueprint Medicines Corporation Map4k1 inhibitors
WO2023001794A1 (en) 2021-07-20 2023-01-26 Astrazeneca Ab Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
KR20100044251A (ko) 2007-08-15 2010-04-29 싸이토키네틱스, 인코포레이티드 특정 화학 물질, 조성물 및 방법
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US8980916B2 (en) 2011-10-27 2015-03-17 Merck Sharp & Dohme Corp. Factor IXa inhibitors
RS61919B1 (sr) * 2015-06-25 2021-06-30 Univ Health Network Inhibitori hpk1 i postupci za njihovo korišćenje
WO2018049214A1 (en) * 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US11180482B2 (en) * 2016-11-30 2021-11-23 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
MX2019011511A (es) * 2017-03-30 2019-11-18 Hoffmann La Roche Naftiridinas como inhibidores de cinasa 1 progenitora hematopoyetica (hpk1).

Similar Documents

Publication Publication Date Title
JP2021531311A5 (https=)
JP2021532109A5 (https=)
RU2010111551A (ru) Замещенные индольные производные и способы их применения
JP2020512974A5 (https=)
RU2010111550A (ru) 2,3-замещенные индольные производные для лечения вирусных инфекций
RU2016102036A (ru) Производное хинолина
RU2013126041A (ru) Пиразолопиридины и пиразолопиридины и их применение в качестве ингибиторов tyk2
JP2021513534A5 (https=)
JP2012526728A5 (https=)
JP2019510798A5 (https=)
JP2017137291A5 (https=)
AR076486A1 (es) Inhibidores de fosfoinositida 3 kinasa y composiciones farmaceuticas que los contienen.
JP2009543802A5 (https=)
JP2018526367A5 (https=)
JPWO2020023560A5 (https=)
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
RU2016114866A (ru) Замещенные аминопиримидиновые соединения и способы их использования
JP2020500866A5 (https=)
JP2012505871A5 (https=)
JPWO2018183956A5 (https=)
JP2013512903A5 (https=)
JP2017523169A5 (https=)
RU2012153164A (ru) Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательного пути
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
RU2013108348A (ru) Конденсированные гетероарилы и их применение